Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Wang, Lijuna | Wu, Qia | Zhu, Shana | Li, Zhiyua | Yuan, Jingpingb | Liu, Linb | Yu, Dehuab; c | Xu, Zhilianga | Li, Juanjuana | Sun, Shengronga; * | Wang, Changhuac; *
Affiliations: [a] Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China | [b] Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China | [c] Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, China
Correspondence: [*] Corresponding authors: Shengrong Sun, Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, 99 Zhang Zhidong Road, Wuhan 430060, Hubei, China. E-mail: sun137@sina.com.ChanghuaWang,DepartmentofPathophysiology,SchoolofBasicMedicalSciences,WuhanUniversity,Wuhan430060,Hubei,China.E-mail:chwang0525@whu.edu.cn.
Abstract: DNER, Delta/Notch-like epidermal growth factor (EGF)-related receptor, is a neuron-specific transmembrane protein carrying extracellular EGF-like repeats. The prognostic value of DNER in prostate cancer has not been evaluated. Here we showed that the up-regulation of DNER protein was observed in prostate cancer detected by immunohistochemistry (IHC) and quantum dot-based immunofluorescent imaging and quantitative analytical system (QD-IIQAS). However, a higher accuracy of measurements of DNER expression in prostate cancer was found by QD-IIQAS than by IHC (AUC = 0.817 and 0.617, respectively). DNER was significantly higher in patients undergoing bone metastasis (P = 0.045, RR = 3.624). In addition, DNER overexpression was associated with poor overall survival (OS) (P = 0.028, adjusted HR = 8.564) and recurrence-free survival (RFS) (P = 0.042, adjusted HR = 3.474) in patients suffering prostate cancer. Thus, QD-IIQAS is an easy and accurate method for assessing DNER and the DNER expression was an independent prognostic factor in prostate cancer.
Keywords: Quantum dot-based immunofluorescent imaging, DNER, prognostic value, prostate cancer
DOI: 10.3233/CBM-171107
Journal: Cancer Biomarkers, vol. 22, no. 4, pp. 683-691, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl